Gefitinib
EGFR-Kinase inhibitor / Potent and selective EGFR kinase inhibitor (IC50 = 23-79 nM)1. Inhibits EGFR autophosphorylation and inhibits tumor growth in vivo2. Enhances efficacy of cytotoxic agents3. Inhibits growth factor production and angiogenesis4. Clinically useful anticancer agent.
Biochemicals & reagents
184475-35-2
NSC 17821; NSC 23880
1) Baselga et al. (2000), ZD1839 (‘Iressa’) as an anticancer agent; Drugs, 60 33 2) McKillop et al. (2005), Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor; Mol. Cancer Ther., 4 641 3) Sirotnak et al. (2000), Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase; Clin. Cancer Res., 6 4885 4) Ciaradiello et al. (2001), Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor; Clin. Cancer Res., 7 1459
RT
TARGET: Kinase -- PATHWAY: Cytotoxicity; EGF -- RESEARCH AREA: Angiogenesis; Cell death -- DISEASE AREA: Cancer